Current status of mannose receptor-targeted drug delivery for improved anti-HIV therapy

Rojekar, Satish; Gholap, Amol D.; Togre, Namdev; Bhoj, Priyanka; Haeck, Clement; Hatvate, Navnath; Singh, Nidhi; Vitore, Jyotsna; Dhoble, Sagar; Kashid, Snehal; Patravale, Vandana

doi:10.1016/j.jconrel.2024.06.002

Cited by 5 publications

References 228 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Achieving Optimal Health With Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon

Gholap,

Khuspe,

Pardeshi

et al. 2024

Advanced Therapeutics

View full text Add to dashboard Cite

Host‐directed therapies (HDTs) have emerged as a promising strategy to combat viral infections by modifying host factors and immune responses to restrict viral replication and improve patient outcomes. This review summarizes the latest advances and future potential of HDTs in antiviral therapy. With developments in genomics and proteomics, new host targets essential for viral replication have been identified. Gene‐editing tools, such as CRISPR‐Cas9, enable precise manipulation of host genes linked to viral processes, paving the way for innovative HDTs. Emerging approaches, including RNA interference and viral interference, further demonstrate the potential to specifically modify host factors to inhibit viral replication. Additionally, probiotics are being explored for their capacity to enhance immune responses and modulate gut microbiota, offering a natural and safe method for boosting antiviral defenses. Despite these advancements, significant challenges remain, particularly in deciphering complex host–virus interactions and ensuring the safety and efficacy of these therapies. Continued research and clinical evaluation are essential to realize the full potential of HDTs. This review provides a comprehensive overview of current HDT strategies, emphasizing their promise in shaping future antiviral interventions.

show abstract

Achieving Optimal Health With Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon

Gholap,

Khuspe,

Pardeshi

et al. 2024

Advanced Therapeutics

View full text Add to dashboard Cite

show abstract

pH‐Responsive Protein‐Polycation Nanocarriers for Efficient Eradication of Bacterial Biofilms and Intracellular Bacteria

Amier,

Ji,

Xun

et al. 2024

Macromol. Rapid Commun.

View full text Add to dashboard Cite

Bacterial biofilms and intracellular pathogens pose significant challenges in eradication, often leading to persistent infections that are difficult to treat. To address this issue, the hydrophobic biofilm dispersant D‐tyrosine is encapsulated within protein‐polycation nanoparticles, designed using a mannose‐terminated cationic polymer and concanavalin through electrostatic interactions. Thermodynamic studies reveal that free mannosyl groups on the nanoparticle surface promote spontaneous binding to receptor molecules mimicking those on bacterial biofilms and host cells. Under mildly acidic conditions, the nanoparticles reduce in size from 550 to ≈48 nm within 2 h, releasing 76% of encapsulated D‐tyrosine. The combination of mannose targeting, particle size reduction, and controlled D‐tyrosine release enable the nanoparticles to eliminate 70%–80% of the Pseudomonas aeruginosa and Staphylococcus aureus biofilm biomass at minimum bactericidal concentration (MBC) and 2MBC while eradicating 8 log of bacteria embedded within the biofilm. In an intracellular Pseudomonas aeruginosa infection model using RAW 264.7 macrophages, the nanoparticles at 2MBC eliminate over 95% of the intracellular bacteria without inducing an increase in the inflammatory cytokine interleukin‐6. These protein‐polycation nanoparticles, which activate their antimicrobial properties under acidic conditions, efficiently penetrate bacterial biofilms and host cell barriers via their mannose‐rich surface, offering a promising strategy for the treatment of persistent infections.

show abstract

Enhancing antiretroviral efficacy: a comprehensive exploration of liposomal and receptor-targeted drug delivery for HIV

Woldu

2024

Discov Med

View full text Add to dashboard Cite

Current status of mannose receptor-targeted drug delivery for improved anti-HIV therapy

Cited by 5 publications

References 228 publications

Achieving Optimal Health With Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon

Achieving Optimal Health With Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon

pH‐Responsive Protein‐Polycation Nanocarriers for Efficient Eradication of Bacterial Biofilms and Intracellular Bacteria

Enhancing antiretroviral efficacy: a comprehensive exploration of liposomal and receptor-targeted drug delivery for HIV

Contact Info

Product

Resources

About